UroGen Pharma (URGN) Research & Development (2017 - 2026)

UroGen Pharma (URGN) has 10 years of Research & Development data on file, last reported at $15.6 million in Q1 2026.

• Quarterly Research & Development fell 21.51% year-over-year to $15.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62.8 million (up 2.13% YoY) and the FY2025 annual result came in at $67.1 million, up 17.43% from the prior year.
• Research & Development grew to $15.6 million in Q1 2026, from $14.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $19.9 million in Q1 2025 to a low of $10.2 million in Q3 2023.
• A 5-year average of $14.0 million and a median of $14.0 million in 2025 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development slipped 21.93% — and 2024, when it surged 32.96%.
• Tracing URGN's Research & Development over 5 years: stood at $14.5 million in 2022, then fell by 21.93% to $11.3 million in 2023, then jumped by 31.78% to $14.9 million in 2024, then decreased by 3.89% to $14.3 million in 2025, then advanced by 8.96% to $15.6 million in 2026.
• The last three Research & Development figures came in at $15.6 million (Q1 2026), $14.3 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.